Nature

Using Gene Editing in Living Organisms to Lower Blood Fat Levels by Targeting ANGPTL3

Updated

Abstract

A single infusion of a CRISPR-based treatment resulted in over 90% reduction of circulating ANGPTL3 protein in nonhuman primates.

  • Targeted inactivation of ANGPTL3 is linked to reductions of approximately 40 to 50% in low-density lipoprotein cholesterol (LDL-C).
  • The treatment caused a reduction of 50 to 70% in triglyceride levels in hyperlipidemic models.
  • The gene-editing approach demonstrated no detectable off-target effects at around 3000 candidate sites.
  • Durability of the ANGPTL3 inactivation was confirmed for up to 3 years after a single dose in nonhuman primates.
  • The findings support the initiation of a first-in-human clinical trial for patients with refractory hyperlipidemia syndromes.

Simplified

Full Text

Full text is available at the source.

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free